Changes in Rosuvastatin Pharmacokinetics During Postnatal Ontogenesis in Rats

Area of Science:

• Pharmacology
• Pediatric Medicine
• Drug Development

Background:

• Familial hypercholesterolemia requires statin therapy in children with high LDL-C.
• Limited pharmacokinetic data exists for rosuvastatin in children under six years old.
• Case reports are the primary source for efficacy and safety information in this age group.

Purpose of the Study:

• To investigate developmental changes in rosuvastatin pharmacokinetics in rats.
• To establish a basis for developing clinical formulations for pediatric patients (<6 years).
• To inform dosing strategies for young children requiring statin treatment.

Main Methods:

• Examined rosuvastatin pharmacokinetics in rats from 1 to 42 days of age.
• Administered a single intraperitoneal dose of 5 mg/kg rosuvastatin.
• Calculated pharmacokinetic parameters (Vd, CL, AUC) using simulations.

Main Results:

• Rosuvastatin clearance (CL) and volume of distribution (Vd) increased significantly between 2-3 weeks of age.
• Drug exposure (AUC) was up to 13 times higher in rats ≤14 days old compared to 42-day-old rats.
• This indicates substantial developmental changes in drug metabolism and distribution.

Conclusions:

• Interspecies scaling suggests dose reduction is a viable strategy for pediatric formulations (2-6 years).
• Further clinical studies are required to confirm appropriate dosing schedules and formulations.
• This research supports the development of targeted statin therapies for young children.